Status:

COMPLETED

Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to investigate the glycaemic control and other clinical parameters in adult patients previously treated with basal insulin (with or without OADs) and switched to IDegLira ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Male or female, age above or equal to 18 years at the time of data collection.
  • Patient diagnosed with T2D greater than or equal to 12 months prior to data collection.
  • The decision to initiate treatment with commercially available IDegLira has been made by the patient and the treating physician before, which is independent from the decision to participate in this study.
  • Treated with basal insulin plus/minus OADs prior to initiating IDegLira.
  • Available and documented HbA1c measurement below or equal to 12 weeks prior to IDegLira initiation.
  • Exclusion criteria:
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
  • Diagnosed with type 1 diabetes mellitus, maturity-onset diabetes of the young, latent autoimmune diabetes in adults, gestational diabetes or any hyperglycaemic state other than T2D.
  • Women known to be pregnant or breastfeeding during the conduct of the study.
  • Patients with basal-bolus insulin prior to IDegLira initiation.
  • Participation in another T2D clinical study that involves any clinical intervention or administration of an investigational drug within 3 months prior to initiating IDegLira.

Exclusion

    Key Trial Info

    Start Date :

    March 22 2022

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    July 15 2022

    Estimated Enrollment :

    175 Patients enrolled

    Trial Details

    Trial ID

    NCT05324462

    Start Date

    March 22 2022

    End Date

    July 15 2022

    Last Update

    November 9 2022

    Active Locations (6)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (6 locations)

    1

    Novo Nordisk Investigational Site

    Medellín, Antioquia, Colombia

    2

    Novo Nordisk Investigational Site

    Barranquilla, Atlántico, Colombia

    3

    Novo Nordisk Investigational Site

    Bogotá, Bogota DC, Colombia

    4

    Novo Nordisk Investigational Site

    Montería, Departamento de Córdoba, Colombia